Results 51 to 60 of about 50,322 (261)

Dermatomyositis: A Multifaceted Autoimmune Connective Tissue Disorder: Series of Seven Cases

Clinical Dermatology Review
Dermatomyositis is a rare connective tissue disorder having a wide array of characteristic cutaneous and systemic manifestations. There is an established paraneoplastic association of malignancy with dermatomyositis which is seen in adult patients as ...
Mrunali Anil Joshi, Pooja Agarwal, Kalgi Baxi, Raju Gisaram Chaudhary, Vama Vijay Patel   +4 more
doaj   +1 more source

Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis

Clinical, Cosmetic and Investigational Dermatology, 2023
Yuxin Zheng, Suiqing Cai Department of Dermatology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, People’s Republic of ChinaCorrespondence: Suiqing Cai, Department of Dermatology, Zhejiang University School of Medicine ...
Zheng Y, Cai S
doaj  

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers

Respirology Case Reports, 2021
We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and ...
Ryosuke Imai, Sumie Ikemura, Torahiko Jinta   +2 more
doaj   +1 more source

Drug-induced dermatomyositis after lacosamide: A case report. [PDF]

, 2018
Here we describe a caseof a woman who had DM after treatment withlacosamide.
Gaffney, Rebecca G., Tarazi, Meera, Werth, Victoria P.   +2 more
core   +1 more source

Risk factors associated with calcinosis of juvenile dermatomyositis [PDF]

, 2008
OBJETIVO: Identificar fatores de risco associados à calcinose em crianças e adolescentes com dermatomiosite juvenil. MÉTODOS: Prontuários de 54 pacientes com dermatomiosite juvenil foram estudados.
AIKAWA, Nádia E., DORIA-FILHO, Ulysses, LIPHAUS, Bernadete L., MARIE, Suely K. N., PIVATO, Francine C. M. M., SALLUM, Adriana M. E., SILVA, Clovis A. A.   +6 more
core   +3 more sources

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Recalcitrant Dermatomyositis Treated With Anifrolumab

ACR Open Rheumatology
Dermatomyositis is an idiopathic inflammatory myopathy which can present with distinctive skin features. Despite the many treatment modalities for the treatment of dermatomyositis some patients remain refractory to treatment.
Shivang Chaudhary, Meghan Baumer, Laura Upton, Samantha Ong, Kristin Smith, Daniel West, Adam Kilian   +6 more
doaj   +1 more source

Amyopathic Dermatomyositis Associated with Histopathological Findings of Organizing Pneumonia and Pulmonary Vasculitis

Balkan Medical Journal, 2017
Background: Clinically, amyopathic dermatomyositis is a clinically distinct subgroup of dermatomyositis characterised by unique dermatological manifestations without muscle involvement. Clinically, amyopathic dermatomyositis is frequently associated with
Jeong Uk Lim, Hye Seon Kang, Yong Hyun Kim, Tae-Jung Kim   +3 more
doaj   +1 more source

Inclusion body myositis: therapeutic approaches. [PDF]

, 2012
The idiopathic inflammatory myopathies are a heterogeneous group of diseases that include dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and other less common myopathies.
Aggarwal, Rohit, Oddis, Chester V
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source